Twenty-nine new members join DF/HCC

Congratulations to the twenty-nine individuals from our seven member institutions who have recently joined DF/HCC. Sophia Adamia, PhD (HMS)Cancer Genetics, LeukemiaResearch focus: The main interest is to understand the molecular basis of hematological malignancies and to take discoveries from a lab bench to "near-bedside" clinical settings. Parul Bhargava, MBBS (BIDMC)Lymphoma and MyelomaResearch focus: The research focus is primarily in the area of biomarkers in hematopoietic malignancies, in particular those that can be readily applied in clinical laboratories to aid in their accurate diagnostic subclassification and/or prognosis. Brett Bouma, PhD (MGH)Area of InterestResearch focus: The focus is on design of clinical trials evaluating novel therapeutics for molecularly-defined subsets of non-small cell lung cancer, with a parallel focus in translational research and an emphasis on understanding the molecular mechanisms of resistance to targeted therapies.Gabriel Brooks, MD (DFCI)Area of InterestResearch focus: The focus is on design of clinical trials evaluating novel therapeutics for molecularly-defined subsets of non-small cell lung cancer, with a parallel focus in translational research and an emphasis on understanding the molecular mechanisms of resistance to targeted therapies.Wei Ding, PhD (UMB) Area of InterestResearch focus: The focus is on design of clinical trials evaluating novel therapeutics for molecularly-defined subsets of ...
Source: DF/HCC: Latest News - Category: Cancer & Oncology Source Type: news